Aug 12, 2020
New Recommendations Aim to Increase Capacity for Specialized Care for Adults Living with Sickle Cell Disease
Jun 17, 2020
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
Jun 17, 2020
In Recognition of World Sickle Cell Day, The Sickle Cell Foundation of Tennessee Launches Feed Our Families Campaign, Webinar and Podcast
Jun 13, 2020
EHA25Virtual: Adult Patients With Sickle Cell Disease May Be at Increased Risk of Adverse Outcomes From COVID-19
Jun 11, 2020
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
May 11, 2020
Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer
May 07, 2020
Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 07, 2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
May 05, 2020
Rigel Reports First Quarter 2020 Financial Results and Provides Business Update
Mar 17, 2020
Sickle Cell Anemia Industry Outlook to 2026 Featuring CRISPR Therapeutics, Global Blood Therapeutics, Novartis, Pfizer, and Vertex Pharmaceuticals
Jan 22, 2020
Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease
Jan 06, 2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
Nov 25, 2019
California to Expand Innovative Adult Sickle Cell Disease Clinics Statewide
Nov 18, 2019
New Sickle Cell Drug With Oklahoma Roots Receives FDA Approval
Nov 14, 2019
Sickle Cell Disease (SCD) Epidemiology Forecast to 2028: Focus on Turkey, Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina
Nov 07, 2019
Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition
Nov 07, 2019
Cold Agglutinin Disease (CAD) Epidemiology Report 2019: Total Prevalent Cases the 10EM was Found to be 29,077 in 2017 - Forecast to 2028
Nov 06, 2019
New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders
Nov 04, 2019
Sickle Cell Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Oct 30, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera